🔎 Trials Near Me

Início › Leucemia Mieloide Aguda › Wisconsin › Madison

Ensaios clínicos de Leucemia Mieloide Aguda em Madison, WI

16 estudos para Leucemia Mieloide Aguda estão buscando participantes em locais em Madison e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.

Texto oficial do estudo (Inglês)

Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
  • William S Middleton VA Medical Center, Madison
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

RecrutandoFase 2
  • William S Middleton VA Medical Center, Madison
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

RecrutandoFase 2
  • William S Middleton VA Medical Center, Madison
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

RecrutandoFase 2
  • William S Middleton VA Medical Center, Madison
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

RecrutandoFase 2
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Idades de 18 a 59 · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

RecrutandoFase 3
  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison
6 Months – 21 Years · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT04293562

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

RecrutandoFase 3
  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Idades de 1 a 25 · Todos os sexos · Atualizado em 4 de set. de 2026 · NCT07022678

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

RecrutandoFase 1/2
  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Até 22 anos · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04726241

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

RecrutandoFase 3
  • University of Wisconsin, Madison
Idades 18 e acima · Todos os sexos · Atualizado em 20 de ago. de 2026 · NCT07007312

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

RecrutandoEstudo observacional
  • University of Wisconsin - Madison, Madison
Todas as idades · Todos os sexos · Atualizado em 6 de jul. de 2026 · NCT01351545

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

RecrutandoFase 1
  • University of Wisconsin Carbone Cancer Center, Madison
Idades 18 e acima · Todos os sexos · Atualizado em 14 de mai. de 2026 · NCT06222580

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

RecrutandoFase 1
  • University of Wisconsin Carbone Cancer Center, Madison
Até 21 anos · Todos os sexos · Atualizado em 22 de abr. de 2026 · NCT05101551

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

RecrutandoFase 1
  • University of Wisconsin Hospital and Clinics, Madison
Idades 18 e acima · Todos os sexos · Atualizado em 13 de mar. de 2026 · NCT05735184

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

RecrutandoFase 1
  • University of Wisconsin Carbone Cancer Center, Madison
7 Months – 21 Years · Todos os sexos · Atualizado em 16 de out. de 2025 · NCT02508038

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

RecrutandoFase 1
  • University of Wisconsin Clinical Science Center, Madison
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2025 · NCT06501196

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

RecrutandoVoluntários saudáveis bem-vindos
  • University of Wisconsin, Madison
Idades de 18 a 120 · Todos os sexos · Atualizado em 25 de jul. de 2025 · NCT05237258

Ensaios de Leucemia Mieloide Aguda em outras cidades

Outros estudos em Madison

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.